Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-08-09 Option Award | 2023-08-09 4:30 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 75,000 | $0 | 75,000 (Direct) | View |
| 2023-05-05 Option Award | 2023-05-05 4:00 pm | N/A 2026-05-05 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 75,000 | $0 | 75,000 (Direct) | View |
| 2023-03-09 Option Award | 2023-03-09 3:07 pm | N/A N/A | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 150,000 | $0 | 151,445 (Direct) | View |
| 2022-11-04 Option Award | 2022-11-08 10:23 am | N/A 2032-11-04 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2022-03-10 Option Award | 2022-03-14 11:25 am | N/A 2032-03-10 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 80,000 | $0 | 80,000 (Direct) | View |
| 2021-03-11 Option Award | 2021-03-15 5:10 pm | N/A 2031-03-11 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 40,000 | $0 | 40,000 (Direct) | View |
| 2020-03-16 Option Award | 2020-03-18 4:46 pm | N/A 2030-03-16 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 45,400 | $0 | 45,400 (Direct) | View |
| 2019-09-18 Option Award | 2019-09-20 4:30 pm | N/A 2029-09-18 | Aquestive Therapeutics Inc. | AQST | Marshall Ken W. SVP, Chief Commercial Officer | 66,000 | $0 | 67,445 (Direct) | View |